文献速递妇科肿瘤

沉默RBP2基因对卵巢上皮癌SKOV3/DDP细胞增殖、迁移和侵袭的影响及其机制

[Effect of RBP2 gene silencing on proliferation, migration and invasion of ovarian epithelial cancer SKOV3/DDP cells and its mechanism].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2022-01-01

该研究通过建立稳定下调RBP2表达的顺铂耐药卵巢癌细胞株SKOV3/DDP-RBP2i,发现下调RBP2可抑制细胞增殖、迁移和侵袭,促进凋亡,机制可能与抑制上皮-间质转化有关;裸鼠移植瘤实验及TCGA数据分析进一步支持RBP2与肿瘤生长、转移及不良预后相关。

要点

  • 下调RBP2表达后SKOV3/DDP细胞增殖能力明显下降,第5天增殖活性低于两对照组。
  • 下调RBP2表达后细胞凋亡率升高,侵袭细胞数和划痕愈合率降低。
  • 下调RBP2表达后E-cadherin表达升高,N-cadherin和vimentin表达降低。

核心结论

  • 下调SKOV3/DDP细胞中RBP2表达可抑制细胞迁移和侵袭,机制可能与抑制上皮-间质转化有关。

研究设计与样本

  • 建立稳定下调RBP2表达的顺铂耐药卵巢癌细胞株SKOV3/DDP-RBP2i,并设阴性对照组和空白对照组。
  • 采用CCK-8法检测增殖,流式细胞术检测凋亡,划痕实验和Transwell侵袭实验检测迁移和侵袭。
  • 采用RT-qPCR和Western blot检测上皮-间质转化相关分子标志物表达。
  • 通过裸鼠移植瘤实验验证RBP2对卵巢癌生长的影响,并采用TCGA数据库卵巢癌临床数据分析RBP2表达与肿瘤转移及患者预后的关系。

主要发现

  • 第5天SKOV3/DDP-RBP2i组、阴性对照组和空白对照组增殖活性分别为(56.67±4.16)%、(84.67±3.51)%和(87.00±4.00)%,差异有统计学意义(P<0.001)。
  • SKOV3/DDP-RBP2i组凋亡率为(14.19±1.50)%,高于阴性对照组(8.77±0.75)%和空白对照组(7.48±0.52)%(P<0.001)。
  • SKOV3/DDP-RBP2i组侵袭细胞数为(55.20±2.39)个,低于阴性对照组(82.60±5.18)个和空白对照组(80.80±7.26)个(P<0.001)。
  • SKOV3/DDP-RBP2i组划痕愈合率为(28.47±2.72)%,低于阴性对照组(50.58±4.06)%和空白对照组(48.92±4.63)%(P<0.001)。
  • SKOV3/DDP-RBP2i组E-cadherin mRNA和蛋白表达高于阴性对照组(P=0.015,P<0.001)和空白对照组(P=0.006,P<0.001)。

关键数值与推荐

  • SKOV3/DDP-RBP2i组N-cadherin mRNA和蛋白表达低于阴性对照组(P=0.012,P<0.001)和空白对照组(P=0.005,P<0.001)。
  • SKOV3/DDP-RBP2i组vimentin mRNA和蛋白表达低于阴性对照组(P=0.016,P=0.001)和空白对照组(P=0.011,P=0.001)。
  • 裸鼠接种细胞后自第5周开始,SKOV3/DDP-RBP2i组、阴性对照组和空白对照组肿瘤体积差异有统计学意义,SKOV3/DDP-RBP2i组肿瘤体积小于阴性对照组和空白对照组(P=0.001)。
  • 发生转移的卵巢癌患者RBP2表达量高于未转移者(P=0.043)。
  • RBP2高表达卵巢癌患者中位生存时间为41个月,短于RBP2低表达患者的69个月(P<0.001)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the effect of down-regulation of retinol binding protein 2 (RBP2) expression on the biological characteristics of ovarian cancer cells and its mechanism. Methods: Knockdown of RBP2 and cisplatin (DDP)-resistant ovarian cancer cell line SKOV3/DDP-RBP2i was established, the negative control group and blank control group were also set. Cell counting kit 8 (CCK-8) was used to detect the cell proliferation ability, flow cytometry was used to detect cell apoptosis, scratch test and Transwell invasion test were used to detect cell migration and invasion ability, real-time fluorescent quantitative polymerase chain reaction (RT-qPCR) and western blot were used to detect the expressions of molecular markers related to epithelial-mesenchymal transition (EMT). The effect of RBP2 on the growth of ovarian cancer was verified through experiment of transplanted tumors in nude mice, and the relationships between RBP2 expression and tumor metastasis and patient prognosis were analyzed using the clinical data of ovarian cancer in TCGA database. Results: After down-regulating the expression of RBP2, the proliferation ability of SKOV3/DDP cell was significantly reduced. On the fifth day, the proliferation activities of SKOV3/DDP-RBP2i group, negative control group and blank control group were (56.67±4.16)%, (84.67±3.51) and (87.00±4.00)% respectively, with statistically significant difference (P<0.001). The apoptosis rate of SKOV3/DDP-RBP2i group was (14.19±1.50)%, higher than (8.77±0.75)% of the negative control group and (7.48±0.52)% of the blank control group (P<0.001). The number of invasive cells of SKOV3/DDP-RBP2i group was (55.20±2.39), lower than (82.60±5.18) and (80.80±7.26) of the negative control group and the blank control group, respectively (P<0.001). The scratch healing rate of SKOV3/DDP-RBP2i group was (28.47±2.72)%, lower than (50.58±4.06)% and (48.92±4.63)% of the negative control group and the blank control group, respectively (P<0.001). The mRNA and protein expressions of E-cadherin in the SKOV3/DDP-RBP2i group were higher than those in the negative control group (P=0.015, P<0.001) and the blank control group (P=0.006, P<0.001). The mRNA and protein expression of N-cadherin in SKOV3/DDP-RBP2i group were lower than those in the negative control group (P=0.012, P<0.001) and the blank control group (P=0.005, P<0.001). The mRNA and protein expressions of vimentin in SKOV3/DDP-RBP2i group were also lower than those in the negative control group (P=0.016, P=0.001) and the blank control group (P=0.011, P=0.001). Five weeks after the cells inoculated into the nude mice, the tumor volume of SKOV3/DDP-RBP2i group, negative control group and blank control group were statistically significant different. The tumor volume of SKOV3/DDP-RBP2i group was smaller than those of negative control group and blank control group (P=0.001). Bioinformatics analysis showed that the expression of RBP2 in patients with metastatic ovarian cancer was higher than that without metastasis (P=0.043), and the median overall survival of ovarian cancer patients with high RBP2 expression was 41 months, shorter than 69 months of low RBP2 expression patients (P<0.001). Conclusion: Downregulation of the expression of RBP2 in SKOV3/DDP cells can inhibit cell migration and invasion, and the mechanism may be related to the inhibition of EMT. 目的: 探讨下调视黄醇结合蛋白2(RBP2)基因表达对卵巢癌细胞生物学特性的影响及其机制。 方法: 建立稳定下调RBP2表达的顺铂(DDP)耐药卵巢癌细胞株SKOV3/DDP-RBP2i,并设置阴性对照组和空白对照组。采用细胞计数盒8(CCK-8)法检测细胞增殖能力,流式细胞术检测细胞凋亡情况,划痕实验和Transwell侵袭实验检测细胞迁移和侵袭能力,实时荧光定量聚合酶链反应(RT-qPCR)和Western blot法检测上皮-间质转化(EMT)相关分子标志物的表达。通过裸鼠移植瘤实验验证RBP2对卵巢癌生长的影响,采用美国TCGA数据库中的卵巢癌临床数据分析RBP2表达与肿瘤转移和患者预后的关系。 结果: 下调RBP2的表达后,SKOV3/DDP细胞的增殖能力明显下降,第5天时,SKOV3/DDP-RBP2i组、阴性对照组和空白对照组的增殖活性分别为(56.67±4.16)%、(84.67±3.51)%和(87.00±4.00)%,差异开始有统计学意义(P<0.001)。SKOV3/DDP-RBP2i组的凋亡率为(14.19±1.50)%,高于阴性对照组[(8.77±0.75)%]和空白对照组[(7.48±0.52)%,P<0.001];侵袭细胞数为(55.20±2.39)个,低于阴性对照组和空白对照组[分别为(82.60±5.18)个和(80.80±7.26)个,P<0.001)];划痕愈合率为(28.47±2.72)%,低于阴性对照组和空白对照组[分别为(50.58±4.06)%和(48.92±4.63)%,P<0.001]。SKOV3/DDP-RBP2i组细胞中E-cadherin的mRNA和蛋白表达量高于阴性对照组(P=0.015,P<0.001)和空白对照组(P=0.006,P<0.001),N-cadherin的mRNA和蛋白表达量低于阴性对照组(P=0.012,P<0.001)和空白对照组(P=0.005,P<0.001),vimentin的mRNA和蛋白表达量也低于阴性对照组(P=0.016,P=0.001)和空白对照组(P=0.011,P=0.001)。裸鼠接种细胞后,自第5周开始,SKOV3/DDP-RBP2i组、阴性对照组和空白对照组的肿瘤体积差异有统计学意义,SKOV3/DDP-RBP2i组的肿瘤体积小于阴性对照组和空白对照组(P=0.001)。生物信息学分析显示,发生转移的卵巢癌患者RBP2表达量高于未转移者(P=0.043),RBP2高表达卵巢癌患者的生存时间(中位生存时间为41个月)短于RBP2低表达患者(中位生存时间为69个月,P<0.001)。 结论: 下调RBP2表达可抑制卵巢癌细胞的迁移和侵袭能力,其机制可能与抑制EMT有关。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Feng TF, Yao DM, Zheng R, et al. [Effect of RBP2 gene silencing on proliferation, migration and invasion of ovarian epithelial cancer SKOV3/DDP cells and its mechanism]. Zhonghua Zhong Liu Za Zhi. 2022. PMID: 35184457. doi:10.3760/cma.j.cn112152-20200612-00555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。